European Companies Search Engine

EU funding (€8,689,222): Early Interception of Inflammatory-mediated Type 2 Diabetes Hor1 Dec 2022 EU Research and Innovation programme "Horizon"

Overview

Text

The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Olatec Therapeutics B.V., New York-FL, United States.

Creative Commons License The visualizations for "Olatec Therapeutics B.V. - EU funding (€8,689,222): Early Interception of Inflammatory-mediated Type 2 Diabetes" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.